UPDATE: Credit Suisse Starts Akili (AKLI) at Outperform, PT $5

Credit Suisse analyst Judah Frommer initiates coverage on Akili (NASDAQ: AKLI) with a Outperform rating and a price target of $5.00.

The analyst comments "Compelling Safety Profile Balanced by Evolving Efficacy: While the on-label indication for EndeavorRx is adjunct to therapy, we could see a clean side-effect profile encouraging caregivers to push for first-line treatment ahead of pharmacological intervention. Improvements in attention in a lab setting are encouraging, but at the same time, experts indicate a desire for more convincing clinical data, particularly statistically significant benefits on ADHD endpoints that are better tied to empirically real-world benefit."

For an analyst ratings summary and ratings history on Akili click here. For more ratings news on Akili click here.

Shares of Akili closed at $1.95 yesterday.

You May Also Be Interested In

• Raymond James Starts SpyGlass Pharma (SGP) at Outperform
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• New Street Research Upgrades Micron Technology (MU) to Buy